Esperante is a corporate venture capital company as an affiliate of a privately-owned global life science group. The leadership is experienced in the operational management of life science companies and specifically on the development, manufacturing and marketing of prescription pharmaceuticals and in vitro clinical diagnostic tests on a worldwide basis. Esperante was established in 2004 and has to date completed 24 pharmaceutical and diagnostic company investments across the US, UK, continental Europe and Israel. 3 exits have been delivered to date: Thiakis (UK) to Wyeth/Pfizer (US), Pinnacle Biologics (US) to Concordia (Canada) and Haemostatix (UK) to Ergomed (UK). 4 portfolio companies are currently publicly listed in the US, Canada and UK. The therapeutics portfolio companies are mainly in Phase 2 or 3 clinical development and two diagnostics companies are in European commercial launch phase. Esperante currently seeks to make initial investments of up to EUR 2,000,000 each in syndication with other investors with the intent of generating exit through sale or other liquidity outcomes within a period of 3 years.